Stock Taper
MANE
VERADERMICS, INCORPORATED
NYSE
$97.93
▼ DOWN 3.81% (-3.88)

KEY STATISTICS

Market Cap$4.09 B
52w High$131.24
52w Low$32.00
Dividend Yield
Frequency
P/E-31.18
Volume623.48K
Shares Out.41.78M

COMPANY

LEADERSHIP

Reid Waldman
CHIEF EXECUTIVE
Reid Waldman

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 4, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
37

PRICE TARGET

Target High$182.00
Target Low$136.00
Target Median$170.00
Target Consensus$162.67

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.
NOV
10
TUE

PRICE

$97.93 ▼ DOWN 3.81% (−$3.88)
$97.50$99.00$101$1029:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM97.93

About Veradermics, Incorporated

https://www.veradermics.com ↗

Veradermics, founded in 2019 in New Haven, CT, develops novel dermatologic and aesthetic therapeutics, including non-hormonal hair loss treatments and immunotherapy patches for conditions like alopecia, warts, and molluscum contagiosum.

INDUSTRY

Biotechnology

A PRODUCT VERADERMICS, INCORPORATED IS KNOWN FOR

VDPHL01
VDPHL01

VDPHL01 is a late-stage, non-hormonal oral minoxidil formulation in development for hair loss, aiming to become the first FDA-approved oral treatment for male and female pattern baldness.

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity5
Price To Earnings1
Price To Book1
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
TVTX$65.67COMPARE
HELP$12.18COMPARE
OVID$2.80COMPARE
ABEO$5.92COMPARE
PLYX$2.06COMPARE
XTLB$2.47COMPARE
LSTA$1.69COMPARE
ADIL$5.60COMPARE